PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.99
Negative D/E while GNPX shows 0.00. Joel Greenblatt would look for hidden assets and restructuring catalysts.
-1.96
Net cash position while GNPX shows net debt of 0.29. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.
-2.29
Negative coverage while GNPX shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
0.97
Current ratio 1.25-1.5x GNPX's 0.84. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.